Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)-Reference-Cited by-同舟云学术

Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)

Published:2022-09-22 Issue:12 Volume:57 Page:1803-1809
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Gavriilaki Eleni^ORCID,Labopin Myriam^ORCID,Sakellari Ioanna,Salmenniemi Urpu,Yakoub-Agha Ibrahim^ORCID,Potter Victoria,Berceanu Ana,Rambaldi Alessandro,Hilgendorf Inken^ORCID,Kröger Nicolaus^ORCID,Mielke Stephan,Zuckerman Tsila^ORCID,Sanz Jaime^ORCID,Busca Alessandro^ORCID,Ozdogu Hakan^ORCID,Anagnostopoulos Achilles^ORCID,Savani Bipin^ORCID,Giebel Sebastian^ORCID,Bazarbachi Ali^ORCID,Spyridonidis Alexandros^ORCID,Nagler Arnon^ORCID,Mohty Mohamad^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-022-01830-3.pdf

Reference40 articles.

1. Thein MS, Ershler WB, Jemal A, Yates JW, Baer MR. Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades. Cancer. 2013;119:2720–7. https://doi.org/10.1002/cncr.28129.

2. Alam N, Atenafu EG, Kuruvilla J, Uhm J, Lipton JH, Messner HA, et al. Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation. Bone marrow Transplant. 2015;50:1180–6. https://doi.org/10.1038/bmt.2015.151.

3. Kayser S, Dohner K, Krauter J, Kohne CH, Horst HA, Held G, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011;117:2137–45. https://doi.org/10.1182/blood-2010-08-301713.

4. Jethava YS, Sica S, Savani B, Socola F, Jagasia M, Mohty M, et al. Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia. Bone marrow Transplant. 2017;52:1504–11. https://doi.org/10.1038/bmt.2017.83.

5. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2009;15:1628–33. https://doi.org/10.1016/j.bbmt.2009.07.004.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial;Blood Cancer Journal;2024-08-21

2. Treosulfan- Versus Busulfan-based Conditioning in Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Single-center Retrospective Propensity Score-matched Cohort Study;Transplantation and Cellular Therapy;2024-07

3. Second allogeneic haematopoietic stem cell transplant conditioned with treosulfan and fludarabine is associated with encouraging overall survival and transplant related mortality in late relapse of myeloid malignancies;Bone Marrow Transplantation;2024-06-13

4. Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review;Journal of Geriatric Oncology;2024-04

5. Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT;Bone Marrow Transplantation;2024-03-15